Oprozomib

Description: Oprozomib (PR-047) (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome beta5(IC50=36 nM)/LMP7(IC50=82 nM), is orally bioavailable. Oprozomib also has potential antineoplastic activity. Target: Proteasome, Autophagy. Smiles: COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1. References: Zhou HJ, et al. J Med Chem, 2009, 52(9), 3028-3038.